RVXOldtime ... just as a mental exercise, what if using our Asian connections, we did a China (and Asia) centric study?

Potentially a very large market, by itself. And the BTD, and BoM ad hoc data suggest a high likelihood of success in the next trial (imho). China can literally tell Covid and Cardio/Renal/Diabetic patients that they are trying ABL, and control costs for those patients in a study so much better than the West. And approve/utilize ABL (even if EUA) on their own terms. In other words, the costs could be very low relatively speaking, and compliance very high. With the potential for saving many costs down the road with earlier intervention, if ABL works in the real world. It could potentially be a very quick path to revenues, relatively speaking, and more data that might be useful and interesting around the world in other markets. China gets some clout in the process also.

However, politics, and maybe even not getting data out of China could be issues, and a taint. Not sure?

But at some point getting revenues, or a sale, is going to have to happen. And based on the pps, and the trickle of funding coming in just to keep the lights on suggest sooner would be much better than later. Even if it isn't the shiny respected partnering we have all dreamed about for years. Survival and advancement has to happen though, on terms we can afford and handle. Necessity makes for strange bed fellows sometimes.

Just spit balling ... and making a case for some type of forward moving action.